I appreciate the points that you bring to the table, as both sides of the argument are needed. The only thing that makes it tough for me is how one-sided your argument is to the negative.
There aren't any catalysts you feel can propel the PPS?
It seems like anything short of curing cancer will not suffice, for you.
I just saw DOLV run from .03 to .15 by announcing a new ticker. IPIX ran from .15 to 4.93 on positive phase I results.
Even with a fully diluted OS, Oncolix will still have a great share structure. Most of the OTC is full of diluted pigs, so that is a huge positive.
There are lots of positives here, but for some reason they don't matter in your book.
Ticker change is important as it will bring more validity to the merger and more eyes here once complete. This company has the backing of some big players like Ernest Mario Glaxo. Oncolix has 34 patents, which is no small feat, especially in OTC land. Acquiring more drugs that are trial ready to add to the pipeline is important so that investors won't feel like we have all of our eggs in the basket of Prolanta. The list of positives is even more extensive than this, but these are just a few examples.
As you know, you can literally go into ANY OTC stock and dig up all the same dirt you're throwing up about AEPP. It's all pretty standard stuff. What is hard to find is any of the positive stuff that Oncolix has in any of the other OTC stocks, which for some reason you refuse to recognize as being even remotely significant.
You literally have nothing good to say about this company?
I mean it's trading on the OTC at .05!? If we wanted perfect pharmas to invest in, we would be buying companies on the Nasdaq at $50-$100 per share.
We KNOW there are flaws here, but we also KNOW that there are some positives here.
What does Oncolix need to do to get YOUR seal of approval?
Just curious.
